William Lis
- SEC Documents
- Filings
- Personal financials
- Insider transactions
- Previous Companies
-
Portola Pharmaceuticals
(NASDAQ:PTLA)
Sample Contracts with William Lis
Purchase and Sale Agreement (May 9th, 2017)
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
This letter sets forth the amended terms and conditions of your employment with Portola Pharmaceuticals, Inc. (Portola or the Company), effective May 1, 2017.
This letter sets forth the terms and conditions of your part-time employment with Portola Pharmaceuticals, Inc. (Portola or the Company), effective February 1, 2017.
On behalf of Portola Pharmaceuticals, Inc. ("Portola" or the "Company"), I am pleased to offer you an exempt position of Executive Vice President, Chief Commercial and Business Officer reporting directly to me. This role will be a member of the Portola executive committee.
This First Amendment of the License and Collaboration Agreement (this "First Amendment") is made and effective as of April 7, 2014 (the "First Amendment Effective Date") by and between Biogen Idec MA Inc., a corporation organized and existing under the laws of Massachusetts, having its principal place of business at 14 Cambridge Center, Cambridge, Massachusetts ("Biogen Idec") and Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA ("Portola"). Biogen Idec and Portola are referred to individually as a "Party" and collectively as the "Parties."
This SECOND AMENDMENT TO LEASE (this "Amendment") is made and entered into as of the 14th day of March, 2014, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and PORTOLA PHARMACEUTICALS, INC., a Delaware corporation ("Tenant").
This FIRST AMENDMENT TO LEASE (First Amendment) is made and entered into as of the day of May, 2010, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (Landlord), and PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (Tenant).
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Vice President, Business & Commercial Operations, reporting to me.
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Executive Vice President, Research and Development, reporting to me.
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
This SECOND AMENDED AND RESTATED LICENSE AGREEMENT (the Agreement) is executed as of 20th day of December, 2010 (the Effective Date) by and between PORTOLA PHARMACEUTICALS, INC., having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA, 94080, United States (hereinafter referred to as Portola) and ASTELLAS PHARMA INC., having its principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (hereinafter referred to as Astellas). References to either party in this Agreement shall be deemed to include all Affiliates (hereinafter defined) of such party.
This CLINICAL COLLABORATION AGREEMENT (the Agreement) is entered into and made effective as of October 16, 2012 (the Effective Date), by and among Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (Portola), Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having its principal place of business at 345 Park Avenue, New York, NY 10154 (BMS), and Pfizer Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, New York 1017 (Pfizer). Each of Portola, BMS and Pfizer are referred to individually as a Party and collectively as the Parties.
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Executive Vice President, Research and Development, reporting to me.
On behalf of Portola Pharmaceuticals, Inc. (Portola or the Company), I am pleased to offer you an exempt position of Vice President, Business & Commercial Operations, reporting to me.
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
This CLINICAL COLLABORATION AGREEMENT (the Agreement) is entered into and made effective as of October 16, 2012 (the Effective Date), by and among Portola Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080, USA (Portola), Bristol-Myers Squibb Company, a corporation organized and existing under the laws of Delaware, having its principal place of business at 345 Park Avenue, New York, NY 10154 (BMS), and Pfizer Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at 235 East 42nd Street, New York, New York 1017 (Pfizer). Each of Portola, BMS and Pfizer are referred to individually as a Party and collectively as the Parties.
This FIRST AMENDMENT TO LEASE (First Amendment) is made and entered into as of the day of May, 2010, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (Landlord), and PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (Tenant).
This SECOND AMENDED AND RESTATED LICENSE AGREEMENT (the Agreement) is executed as of 20th day of December, 2010 (the Effective Date) by and between PORTOLA PHARMACEUTICALS, INC., having its principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, CA, 94080, United States (hereinafter referred to as Portola) and ASTELLAS PHARMA INC., having its principal place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (hereinafter referred to as Astellas). References to either party in this Agreement shall be deemed to include all Affiliates (hereinafter defined) of such party.
THIS THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the Agreement) is entered into as of the 18th day of November, 2011, by and among PORTOLA PHARMACEUTICALS, INC., a Delaware corporation (the Company), and the investors listed on Exhibit A hereto, referred to hereinafter as the Investors and each individually as an Investor.